Glucagon receptor activation likely requires threshold concentrations
As GLP-1s change from short-term interventions to lifelong cardiometabolic therapies, the home becomes the main environment for ongoing weight management and even preventive health maintenance
For example, semaglutide 2.4 mg showed a mean change of -14.9% at 68 weeks vs -2.4% with placebo in one major trial
Limitations of the TRIUMPH-1 results The results of TRIUMPH-1 have only come through a press release, not the publication of a peer-reviewed journal

Thats why we combed Reddit to find out what people are currently talking about in obesity and GLP-1 communities and asked the following medical experts to respond to readers most pressing questions: Kia Mitchell, MD Double board-certified family and obesity medicine physician and founder of the International Womens Obesity Network Marsha Novick, MD, FAAFP Spokesperson for The Obesity Society and board member of the American Board of Obesity Medicine Richele Corrado, DO, MPH Spokesperson for The Obesity Society and medical director, internist, and obesity medicine physician at Revolution Medicine, Health & Fitness Sherrie Singh-Bryan, PharmD, CDCES Clinical pharmacist and certified diabetic care and education specialist at Winn Army Community Hospital in Fort Stewart, Georgia Editors note: These interviews have been edited for length and clarity
Have regained weight in the past after dieting